MGC Pharmaceuticals has signed a deal to distribute its ArtemiC product worldwide, following successful trials in COVID-19 patients.
The firm has signed a three year exclusive worldwide supply and distribution agreement with European nutraceuticals producer, Swiss PharmaCan AG, for the distribution of ArtemiC Rescue as a food supplement.
It follows the completion of a successful phase II double-blind, placebo controlled clinical trial on 50 COVID-19 patients to evaluate the safety and efficacy of the anti-inflammatory product.
ArtemiCTM is a clinically tested food supplement containing four natural ingredients consisting of artemisinin, curcumin, boswellia serrata, and Vitamin C.
This agreement represents the first sales of ArtemiCTM as a food grade product and provides MGC Pharma direct access to the rapidly growing markets that are still reporting high numbers of COVID-19 cases.
Results from the trail published in December 2020, highlight that ArtemiCTM Rescue demonstrates the ability to prevent deterioration of COVID-19 patients and achieve faster clinical improvement, to reduce symptoms and pain associated with the virus and has a full safety and efficacy profile with no drug-adverse events.
The product has the potential to assist in reducing the pressure on healthcare systems and support coping with hospitalised patients, as well as displaying the versatility to be used in the community.
As ArtemiCTM Rescue is focused on an anti-inflammatory effect and reducing and prevention of cytokine storm – an overreaction of the immune system, where the body starts to attack its own cells – a wide range of potential indications will be considered for future development.
Under the terms of the agreement, MGC Pharma will provide ArtemiCTM Rescue to SPC to distribute as a food supplement worldwide (with the exception of excluded territories; Thailand, Myanmar, Israel, CIS countries and Ukraine).
The company will also produce and provide an additional supplement called ArtemiCTM Support which is specifically designed for daily consumption to support and maintain the strength of the human immune system.
Roby Zomer, co-founder and managing director of MGC Pharma, commented: “Following the successful results achieved from our ArtemiCTM Phase II clinical trial in December last year, we are very pleased to have signed this Agreement with Swiss PharmaCan AG for the worldwide distribution of ArtemiCTM as a food supplement as It provides full product validation of ArtemiCTM and its therapeutic benefits.”
Michel Fässler, CEO and member of the board of Swiss PharmaCan AG, added: “We are very happy with the successful cooperation between MGC and Swiss PharmaCan AG.
“The potential of ArtemiC™ is unlimited and a viable, natural solution in the current crisis, offering to so many people possible help and alleviation of their suffering.”
- Malta gives green light to three new cannabis clubs
- European Commission must address ‘inequality’ in access to medicinal cannabis across EU
- 1 in 8 older US adults now use cannabis products, finds study
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Advocacy6 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- Industry6 months ago
New report calls for overhaul of ‘discriminatory’ UK cannabis driving laws
- News4 months ago
Malta: Advocates emphasise positive effects of cannabis reform amid ‘normalisation’ concerns
- Science4 months ago
Five new cannabis studies – ALS, epilepsy, Parkinson’s, chronic pain and blood pressure